New antibody drug shows promise for Hard-to-Treat leukemia
NCT ID NCT03698552
First seen Nov 03, 2025 · Last updated Apr 29, 2026 · Updated 25 times
Summary
This study tested a drug called ADCT-602 in 37 people with a type of leukemia (B-ALL) that had returned or stopped responding to treatment. The drug uses an antibody to target and attack cancer cells. The main goals were to find the safest dose and see if it could shrink or eliminate the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT B ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Comprehensive Cancer
Monrovia, California, 91016, United States
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.